| 2026-07-13 | Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo Yaseen M, Ameer A, Ali Z, Jamali JA, Kumar A, Basit Ali Siddiqui M, Kumari P, Hassaan M, Nanwani P, Abdul Basit M, Lohana N, Qureshi R, Tesfaye M. | Ann Med Surg (Lond) |
| 2026-07-01 | Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials Hamarsheh S, Jaber AR, Abu-Khazneh O, Andonie CR, Majadleh S, Zahran A, Ayesh H. | Endocrinol Diabetes Metab |
| 2026-06-08 | A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance Ludwig MQ, Coester B, Gordian D, Hassan S, Tomlinson AJ, Toure MH, Christensen OP, Lommi G, Moltke-Prehn A, Brown JM, Belmont-Rausch DM, Bau S, Bodur C, Gowda A, Wu I, Kernodle S, Dong V, Ayensu-Mensah M, Sabatini PV, Shin JH, Kirigiti M, Egerod KL, Le Foll C, Lundh S, Gerstenberg MK, Lutz TA, Kievit P, Secher A, Raun K, Myers MG, Pers TH. | Nat Metab |
| 2026-06-07 | Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study Aroda VR, Buzzetti R, Dalskov SM, Jain AB, Larsen JH, Mathieu C, Pratley RE, Videmark A, Watt T, Buse JB. | Lancet Diabetes Endocrinol |
| 2026-06-07 | Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study Buse JB, Bajaj HS, Dalskov SM, Donaldson L, Hansen Duus HH, Fabricius TW, Haluzík M, Lingvay I, Pedersen SD, Pratley RE, Jain AB, REIMAGINE 2 study group. | Lancet Diabetes Endocrinol |
| 2026-06-07 | Cagrilintide-semaglutide: a new option for patients with type 2 diabetes Scheen AJ. | Lancet Diabetes Endocrinol |
| 2026-06-07 | Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study Rosenstock J, Billings LK, Gajria R, Giorgino F, Johansen NB, Klein KR, Thamattoor UK, Buse JB, Jain AB. | Lancet |
| 2026-06-01 | Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide Nielsen MJF, Becker NP, Duus HHH, Kirkeby K, Kupčová V, Lauenborg BW, Low B, Svolgaard O, Witten L. | Clin Pharmacokinet |
| 2026-06-01 | Cellular loci for cagrilintide action identified Hevesi Z, Harkany T. | Nat Metab |
| 2026-05-20 | Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis Rao H, Kumar S, Ali SME, Asif HM, Kumar M, Kumar L, Raja A. | J Diabetes Metab Disord |
| 2026-04-17 | Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial Yamauchi T, Becker NP, Hagemann CA, Huang KC, Kiyosue A, Lim S, Onishi Y, Kosuvaripalli A, Takano T, Ishigaki Y, REDEFINE 5 study group. | Lancet Diabetes Endocrinol |
| 2026-03-16 | Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression Ahmed M, Hassan M, Tahir M, Hussain M, Islam F, Khan GT, Ahsan M, Bin Shafiq S, Ibrahim A, Uddin A, Waqas SA. | Diabetes Obes Metab |
| 2025-11-01 | Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply Davies MJ, Broholm C, Garvey WT. | N Engl J Med |
| 2025-10-07 | In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk Agarwal A, Padwal R, ACP Journal Club Editorial Team at McMaster University. | Ann Intern Med |
| 2025-08-22 | Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors Gu YM, Yuan QN, Li X, He Q, Xu HE, Zhao LH. | Acta Pharmacol Sin |